GlassScriptPhysician profile
Clinton Carroll
NPI 1215100011
$8,164.42
in general payments reported to CMS, 2019-2025
36 companies · $6,240 in 2025
The $6,240 reported for 2025 was more than what 82% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $36.41 · 2021: $20.29 · 2022: $330 · 2023: $765 · 2024: $589 · 2025: $6,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,608 · Food and Beverage: $2,209 · Travel and Lodging: $696 · Education: $80.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,608.00 |
| Food and Beverage | $2,209.45 |
| Travel and Lodging | $696.21 |
| Education | $80.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $5,895.90 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $267.55 | 2021-2025 | |
| Novo Nordisk INC | $198.34 | 2019-2025 | |
| Pharming Healthcare, INC. | $195.66 | 2023-2025 | Ruconest |
| Mesoblast, INC. | $141.72 | 2025 | Ryoncil |
| Ucb, INC. | $135.28 | 2023-2024 | Nayzilam, Briviact |
| Amgen INC. | $133.14 | 2019-2023 | Blincyto, Nplate |
| Vertex Pharmaceuticals Incorporated | $124.11 | 2024 | |
| Springworks Therapeutics, INC. | $122.57 | 2025 | Gomekli |
| Pfizer INC. | $89.55 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $88.10 | 2022-2023 | Eprontia, Zonisade, Xatmep |
| Takeda Pharmaceuticals U.S.A., INC. | $78.68 | 2022-2025 | Livtencity, Elaprase |
| Novartis Pharmaceuticals Corporation | $57.81 | 2022-2023 | |
| Seagen INC. | $57.32 | 2022-2023 | Adcetris |
| Day One Biopharmaceuticals | $47.57 | 2025 | Ojemda |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $46.35 | 2022-2024 | Pyrukynd |
| Medexus Pharma, INC. | $39.88 | 2023 | Ixinity |
| Corium, LLC | $33.29 | 2025 | Azstarys |
| Aucta Pharmaceuticals, INC. | $31.79 | 2024-2025 | Motpoly Xr |
| Bayer Healthcare Pharmaceuticals INC. | $29.94 | 2022 | |
| Immedica Pharma US, INC. | $29.31 | 2025 | Ztalmy |
| Syndax Pharmaceuticals, INC. | $25.96 | 2025 | |
| Krystal Biotech INC | $25.25 | 2024 | Vyjuvek |
| Rare Disease Therapeutics, INC. | $24.48 | 2022 | |
| X4 Pharmaceuticals, INC. | $24.44 | 2025 | Xolremdi |
| Y-Mabs Therapeutics, INC. | $24.42 | 2023 | Danyelza |
| Servier Pharmaceuticals LLC | $23.39 | 2019 | |
| Tris Pharma INC | $23.35 | 2023 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $23.22 | 2023 | |
| Amneal Pharmaceuticals LLC | $20.28 | 2023 | Lyvispah |
| Abbvie INC. | $20.20 | 2019 | |
| Mirum Pharmaceuticals, INC. | $17.99 | 2025 | Cholbam |
| Insulet Corporation | $17.83 | 2019 | |
| Duchesnay USA Incorporated | $17.45 | 2020 | |
| Emmaus Medical, INC. | $16.91 | 2019 | |
| Albireo Pharma, INC. | $15.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.